Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

1
UPDATE 9-Ex-Trump lawyer Cohen reaches plea deal with U.S. prosecutors -reports

4h reuters
NEW YORK (Reuters) - U.S. President Donald Trump’s former lawyer, Michael Cohen, has reached a deal with federal prosecutors in New York to plead guilty to campaign finance violations, bank fraud and tax evasion, news media outlets reported on Tuesday, citing unnamed sources.
NVS NYTAB

109
5 Marijuana Stocks to Watch

9h investorplace - 2
To be honest, I’m not entirely thrilled about investing in marijuana stocks at the moment. Movement toward legalization at the state level in the United States and at the national level in Canada has sent a number of pot stocks soaring. But not all marijuana stocks necessarily are going to be winners. The sector may not be an outright bubble — yet — but there’s certainly a case that rising marijuana-related optimism has lifted all boats, including several that have some leaks.
STZ.B CRON DTK STZ CGC TLRY TAP TWMJF GWPH MRK WEED NVS PFE GWP SMG

19
Glaxo Stock Up This Year So Far: Will the Rally Continue?

9h zacks
So far this year, GlaxoSmithKline plc’s (GSK - Free Report) shares have outperformed the industry, rising 16.5% compared with a 5.6% increase for the industry.
HIK JNJ NVS GSK PFE GSK

6
Glaxo said to seek bids mid-Sept for US$4 bil India sale

9h theedgemarkets
MUMBAI/LONDON (Aug 21): U.K. pharmaceutical giant GlaxoSmithKline Plc has requested bids by mid-September for its US$4.3 billion Indian consumer-health unit, which owns the popular malted milk brand Horlicks, people with knowledge of the matter said.
PEP GSKCONS NVS GSK 500676 RB GSK

6
Magenta Therapeutics: This June IPO Should Be On Your Radar

21h seekingalpha
Ease of access to prior funding, institutional participation and strengthening of leadership team are significant green flags.
MGTA NVS GSK PFE

3
Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose

2018-08-20 zacks
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced that the FDA has approved a supplemental Biologics License Application (sBLA) for its flagship ophthalmology drug, Eylea injection in patients with wet age-related macular degeneration (wet AMD).
REGN TXN NVS SNY

1
Amgen Stock Up This Year So Far: Will the Rally Continue?

2018-08-20 zacks
Amgen, Inc.’s (AMGN - Free Report) stock is up 13.5% this year so far against 6.6% decrease of its industry.
AMGN TXN AGN NVS

3
What's in Store for Cooper Companies' (COO) Q3 Earnings?

2018-08-20 zacks
The Cooper Companies’ (COO - Free Report) third-quarter fiscal 2018 results are scheduled to release on Aug 30, after market close.
DLTR COO VRX BURL NVS ROST

1
Biotech Analysis Central Pharma News: Regeneron's Reversal Of Fortune, Bristol-Myers Squibb's FDA Win, Novo Nordisk's Acquisition

2018-08-20 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
REGN NVS

44
Adamis Looks Cheap Despite Serious Leadership Concerns

2018-08-19 seekingalpha - 2
Adamis' shares fell sharply Aug. 16-17 on the news that generic drug giant Teva had won approval for its generic EpiPen competitor.
NVS ADMP

4
Merck, Eisai Get FDA Approval for Lenvima Label Expansion

2018-08-17 zacks
Merck and Co., Inc. (MRK - Free Report) along with its Japanese partner Eisai Co., Ltd. announced that their tyrosine kinase inhibitor, Lenvima (lenvatinib) has received FDA approval for an expanded indication. Lenvima, has been approved by the FDA for first-line treatment of unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer which is difficult to treat.
MRK AZN AZN RDN NVS FAF

24
CORRECTED--Express Scripts staking out million dollar gene therapies

2018-08-15 reuters - 1
(Reuters) - Express Scripts Holding Co (ESRX.O) built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.
BIIB NVS BLUE CI CVS UNH BMRN ONCE

23
RPT-FOCUS-Express Scripts staking out million dollar gene therapies

2018-08-15 reuters
Aug 15 (Reuters) - Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.
BIIB NVS BLUE CI CVS UNH BMRN ONCE

23
RPT-FOCUS-Express Scripts staking out million dollar gene therapies

2018-08-15 reuters
Aug 15 (Reuters) - Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.
BIIB NVS BLUE CI CVS UNH BMRN ONCE

23
Express Scripts staking out million dollar gene therapies

2018-08-15 channelnewsasia
Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.
BIIB NVS BLUE CI CVS UNH BMRN ONCE

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 66987V109